Retrospective 192 hospitalized patients in Indonesia, 96 patients treated with favipiravir, showing improved recovery with treatment. Only the abstract is currently available.
Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-5.
This study is excluded in the after exclusion results of meta
analysis:
minimal details provided.
{ 'indexed': {'date-parts': [[2022, 3, 30]], 'date-time': '2022-03-30T12:47:26Z', 'timestamp': 1648644446076},
'reference-count': 0,
'publisher': 'Kesmas: Jurnal Kesehatan Masyarakat Nasional',
'issue': '4',
'license': [ { 'start': { 'date-parts': [[2021, 11, 1]],
'date-time': '2021-11-01T00:00:00Z',
'timestamp': 1635724800000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-sa/4.0'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>COVID-19 is a major public health problem, with still questionable specific cure. '
'Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study '
'aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. '
'This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali '
'Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 '
'in the favipiravir group and 96in the non-favipiravir group (remdesivir/oseltamivir). '
'Effectivity was measured by assessing the clinical condition at the end of the isolation '
'period of 14 days. The favipiravir group showed better clinical conditions than the '
'non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 – 4.451; p-value= '
'0.029), seen from being free of fever and respiratory problems. Stratification analysis '
'demonstrated that the clinical improvement was significantly differentin the severe/critical '
'group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious '
'adverse events (AE) found in the use offavipiravir were gastrointestinal disturbances '
'(12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE '
'were found in its use. Appropriate treatment is expected to help in reducing the public '
'health burden.</jats:p>',
'DOI': '10.21109/kesmas.v16i4.5433',
'type': 'journal-article',
'created': {'date-parts': [[2021, 11, 3]], 'date-time': '2021-11-03T01:05:07Z', 'timestamp': 1635901507000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary '
'Referral Hospital, Bali, Indonesia',
'prefix': '10.21109',
'volume': '16',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2437-5072',
'authenticated-orcid': False,
'given': 'Herni',
'family': 'Damayanti',
'sequence': 'first',
'affiliation': []},
{'given': 'I Gede K', 'family': 'Sajinadiyasa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hindun Wilda', 'family': 'Risni', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rani', 'family': 'Sauriasari', 'sequence': 'additional', 'affiliation': []}],
'member': '8818',
'published-online': {'date-parts': [[2021, 11, 1]]},
'container-title': 'Kesmas: National Public Health Journal',
'original-title': [],
'link': [ { 'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 12, 6]],
'date-time': '2021-12-06T13:17:05Z',
'timestamp': 1638796625000},
'score': 1,
'resource': {'primary': {'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/view/5433'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 11, 1]]},
'references-count': 0,
'journal-issue': {'issue': '4', 'published-online': {'date-parts': [[2021, 11, 1]]}},
'URL': 'http://dx.doi.org/10.21109/kesmas.v16i4.5433',
'relation': {},
'ISSN': ['2460-0601', '1907-7505'],
'subject': ['Public Health, Environmental and Occupational Health', 'Health Policy', 'Epidemiology'],
'container-title-short': 'Kesmas: National Public Health Journal',
'published': {'date-parts': [[2021, 11, 1]]}}
Late treatment is less effective
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.